Michael B. Osswald
The University of Texas at San Antonio Health Science Center
Papers
1
Total Citations
62
H-Index
1
About
Michael B. Osswald is a prominent urologic oncologist whose research has significantly advanced the surgical management of high-risk prostate cancer. His key contributions center on multimodal treatment strategies, particularly neoadjuvant therapy before radical prostatectomy for locally advanced disease. His landmark work, the Phase II Southwest Oncology Group Study 9109, demonstrated the feasibility and oncologic benefit of administering systemic therapy prior to surgery for clinical T3/T4 prostate carcinoma. With a five-year follow-up published in the *Journal of Urology* (2002, 62 citations), this study provided critical early evidence that neoadjuvant approaches could improve outcomes for patients with aggressive, non-metastatic disease. Osswald’s research helped shift the paradigm toward combining systemic and surgical treatments, offering a more aggressive, potentially curative path for men with high-risk prostate cancer. His work remains a foundational reference for clinicians and researchers exploring preoperative therapy in urologic oncology.
Research Focus
Key Achievements
Top Papers
- 1